Allegra Orthopaedics Competitors and Similar CompaniesClear all
Allegra Orthopaedics's competitors and similar companies include SKAN, Avinger and Metenova.
 Allegra Orthopaedics Allegra Orthopaedics (formerly known as Advanced Surgical Design and Manufacture) is a company developing orthopaedic prostheses and devices. |  Avinger Avinger is a medical device company that designs, manufactures, and sells image-guided and catheter-based systems for the diagnosis and treatment of peripheral artery disease (PAD). | |||
Founding Date | Founding Date 1994 | Founding Date 1968 | Founding Date 2007 | Founding Date 2009 |
Type | Type Public | Type Subsidiary | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations Lane Cove West, AU HQ | Locations Allschwil, CH HQ Görlitz, DE Okinawa, JP Stein, CH Raleigh, US | Locations Redwood City, US HQ | Locations Mölndal, SE HQ Glen Gardner, US |
Employees | Employees N/A | Employees 1,2161% increase | Employees 714% decrease | Employees 405% decrease |
Valuation ($) | Valuation ($) 2.4 m | Valuation ($) N/A | Valuation ($) 1.8 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $3.2m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $7.7m (FY, 2023) | Revenue (est.) kr133.8m (FY, 2021) |
Cost of goods | Cost of goods $1.4m (FY, 2023) | Cost of goods N/A | Cost of goods $5.6m (FY, 2023) | Cost of goods kr60m (FY, 2021) |
Gross profit | Gross profit $2.6m (FY, 2023) | Gross profit N/A | Gross profit $2m (FY, 2023) | Gross profit kr73.8m (FY, 2021) |
Net income | Net income ($3.6m) (FY, 2023) | Net income N/A | Net income ($18.3m) (FY, 2023) | Net income kr7.5m (FY, 2021) |
For sources of this data, please see the company profile
View Company Profiles
SKAN
HQ
Allschwil, CH
SKAN is a manufacturing company that focuses on isolators and cleanroom devices.
View companyAvinger
HQ
Redwood City, US
Employees
71↓ 4% decrease
Avinger is a medical device company that designs, manufactures, and sells image-guided and catheter-based systems for the diagnosis and treatment of peripheral artery disease (PAD).
View company